...Mohammed Al-Seragi; Yilun Chen; Franck Duong van Hoa NANOBODIES ® (Nbs) have emerged as valuable tools across therapeutic, diagnostic, and industrial applications owing to their small size and consequent ability to bind unique epitopes inaccessible to conventional antibodies. While Nbs retrieved...

...Addison A. Young; Holly E. Bohlin; Jackson R. Pierce; Kyle A. Cottrell Immunotherapy has emerged as a therapeutic option for many cancers. For some tumors, immune checkpoint inhibitors show great efficacy in promoting anti-tumor immunity. However, not all tumors respond to immunotherapies...

... therapeutics targeting the extracellular regulation of BMP signalling, such as BMP9 and Sotatercept, can be related to restoring BMPRII function. Correspondence: Wei Li( [email protected] ) 4 3 2024 25 4 2024 26 4 2024 © 2024 The Author(s) 2024 This is an open access article...

... -acylation and the recent discovery of new enzymes that facilitate protein deacylation, novel small molecules are emerging as potential new therapeutic treatments. Huntington disease (HD) is a devastating, fatal neurodegenerative disease characterized by motor, cognitive, and psychiatric deficits caused...

... biomarkers, and reveal new therapeutic targets for drug discovery. This review gives a high-level overview of the three main translational applications of these studies (diagnostics, prognostics, and therapeutics) by summarising recent literature and outlining the main limitations and future directions...

... maintenance. miRs as therapeutic reagents in tissue regeneration and repair hold great promise and new technologies are currently being designed to facilitate their expression or inhibition. Due to the large amount of miR research in cells and cancer many cellular processes and gene networks have been...

... may open up novel therapeutic options for targeting discrete oncogenic JNK signaling complexes in specific cancer settings. Correspondence: Sharissa L. Latham ( [email protected] ) or David R. Croucher ( [email protected] ) 30 8 2022 28 10 2022 15 11 2022 ©...

... to be considered as therapeutic targets. In the past two decades, around 45 drugs targeting chemokine receptors have been developed, yet only three are clinically approved. The challenging factors include the limited understanding of aberrant chemokine signalling in malignant diseases, high redundancy...

...Thanh Kha Phan; Dilara Ceyda Ozkocak; Ivan Ka Ho Poon Extracellular vesicles (EVs), membrane-bound vesicles that are naturally released by cells, have emerged as new therapeutic opportunities. EVs, particularly exosomes and microvesicles, can transfer effector molecules and elicit potent responses...

... The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2020 BMP9 crosstalk non-coding rna osteogenesis therapeutics Oral and maxillofacial surgery often aims for both functional and esthetic outcomes, both of which are mostly dependent on the underlying...

... and it has been demonstrated that disruption of some of these proteins can cause cancer-specific inhibition of cell growth. For certain targets therapeutically relevant interventions are being investigated, for example, small molecule inhibitors, although none are yet in clinical trials. As the field is now...

...Ruby Macdonald; Katy Barnes; Christopher Hastings; Heather Mortiboys Mitochondrial abnormalities have been identified as a central mechanism in multiple neurodegenerative diseases and, therefore, the mitochondria have been explored as a therapeutic target. This review will focus on the evidence...

... therapeutics to treat PD. Even though the differing phenotypes that result from the disruptions of individual UPR genes in mice have highlighted a remarkable heterogeneity in the UPR signaling network in different tissues [ 18 ], this has not deterred researchers from searching for small molecules...

...Galina Semenova; Jonathan Chernoff p21-Activated kinase 1 (PAK1) has attracted much attention as a potential therapeutic target due to its central role in many oncogenic signaling pathways, its frequent dysregulation in cancers and neurological disorders, and its tractability as a target for small...

...Carlo Viscomi Mitochondrial disorders are a group of genetic diseases affecting the energy-converting process of oxidative phosphorylation. The extreme variability of symptoms, organ involvement, and clinical course represent a challenge to the development of effective therapeutic interventions...

... 12 Pozzo E.D. Giacomelli C. Barresi E. Costa B. Taliani S. Passetti F.D.S. Martini C. 2015 doi:10.1042/BST20150028 13 Werry E.L. Barron M.L. Kassiou M. TSPO as a target for glioblastoma therapeutics 2015 doi:10.1042/BST20150015 14 Janczar...

... circuits during early development. In this case, therapeutic intervention during early development, perhaps before birth, may be required for effective treatment. A better understanding of these different roles will be fundamental not only for establishing new targets for Fragile X interventions, but also...

... research and, as witnessed in 2007, candidate and emerging therapeutics. Thus it is anticipated that the further refinement of CPP technologies will provide drug-delivery vectors, cellular imaging tools, nanoparticulate devices and molecular therapeutics that will have a positive impact on the healthcare...

... 2007 The Biochemical Society 2007 diagnostics epidermal growth factor receptor (EGFR) growth factor signalling therapeutics This short review describes the work that I have been doing for the last 45 years on growth factors, their receptors and signal transduction mechanisms. When I...

...’. The case of GK research illustrates how basic science may culminate in therapeutic advances of human medicine. © 2005 The Biochemical Society 2005 drug discovery genetics glucose glucokinase glucose homeostasis therapeutics 1 To whom correspondence should be addressed (email...